APOE and Alzheimer disease: Specifically, emerging evidence suggests that carriers of APOE4, a major genetic risk factor for AD, exhibit altered pain intensity and sensitivity compared to noncarriers (Romano et al. 2021), potentially due to structural and functional changes in pain‐processing regions, such as the anterior cingulate cortex and insula (Monroe et al. 2012; Romano et al. 2021; Tansley et al. 2022).